Recent studies indicated that combined inhibition of EGFR and CRAF in KRAS-driven models of PDAC prevented tumor development [35]; therefore, there is a growing interest in targeting CRAF as a strategy to treat KRAS mutant tumors [36]. The gene discussed is KRAS; the disease is neoplasm.